Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, HIV/AIDS drug development and treatment, and Monoclonal and Polyclonal Antibodies Research.
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial
A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
Evolution of antibody immunity to SARS-CoV-2
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates
A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch
Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation
Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117
Relationship between intact HIV-1 proviruses in circulating CD4 <sup>+</sup> T cells and rebound viruses emerging during treatment interruption
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells
Hypermethylation of <i>MIR21</i> in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA